Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.

Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

Panelists discuss emerging immunotherapy strategies for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), particularly the combination of BCG with systemic checkpoint inhibitors, noting ...

A panelist discusses how food significantly affects abiraterone absorption, particularly fatty meals, which can increase absorption to dangerous levels, making the microformulation advantageous by ...

In a groundbreaking cross-border collaboration, Cleveland Clinic urologists recently completed the world's first remotely performed robot-assisted high-intensity focused ultrasound (HIFU) focal ...

Panelists discuss how molecular imaging might help with complex renal mass decision-making, potentially identifying aggressive clear cell biology that would warrant radical rather than partial ...

Anne Schuckman, MD, on optimal sequencing strategies, the SWOG 1602 trial, and the emerging role of ctDNA. There has been an explosion in innovation in the non–muscle invasive bladder cancer (NMIBC) ...

The approval is supported by several studies highlighting the efficacy of Rezūm Water Vapor Therapy in patients with larger prostates.

"Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive ...

Key Takeaways Lutetium (177Lu) rhPSMA-10.1 showed higher radiation doses in tumors than in normal organs, indicating a favorable therapeutic index in mCRPC patients. The phase 1 trial demonstrated a ...

MIST utilization increased from 7% in 2015 to 51% in 2022 among men aged 50 to 54. Recent data show that the use of minimally invasive surgical therapies (MISTs) for the management of benign prostatic ...

There has been an explosion of treatment options in non–muscle invasive bladder cancer (NMIBC) in recent years, with even more coming down the pike. Many of these agents have demonstrated encouraging ...